| Entry |
|
|---|
| Name |
Trastuzumab (USAN/INN);
Trastuzumab (genetical recombination) (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN);
Trastuzumab-pkrb;
Trastuzumab-anns;
Trastuzumab-dkst;
Trastuzumab-dttb;
Trastuzumab-qyyp;
Trastuzumab-anns;
Herceptin (TN);
Herzuma (TN);
Kanjinti (TN);
Ogivri (TN) |
|---|
| Product |
|
|---|
| Sequence |
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H147-H203, H264-H324, H370-H428, H229-H'229, H232-H'232, L23-L88, L134-L194, H223-L214) |
|---|
| Type |
Peptide |
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (mixture): | D11560<US> D11934<US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody |
|---|
| Disease |
Breast cancer (HER2 overexpressing) [DS: H00031] Gastric cancer (HER2 overexpressing) [DS: H00018] |
|---|
| Comment |
Monoclonal antibody
|
|---|
| Target |
|
|---|
| Network |
| N10009 | Tyrosine kinase inhibitor to HER2 overexpression/amplification |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC03 Trastuzumab
D03257 Trastuzumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Trastuzumab
D03257 Trastuzumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D03257 Trastuzumab (USAN/INN); Trastuzumab (genetical recombination) (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
D03257 Trastuzumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03257
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03257
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D03257
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
